Laxmi Dental Limited
NSE: LAXMIDENTLMedical Equipment & Supplies
Share price
₹195.92
+1.77% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
66
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹1,078 Cr
P/E ratio
31.0
P/B ratio
4.4
ROCE
15.0%
ROE
14.8%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 15.9% a year against a sector median of 13.1% — 2.9 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 0.2 times its growth rate, on earnings growth of 124%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Laxmi Dental Limited — this one | 124%/yr | 30.4× | — |
| Molbio Diagnostics Limited | — | 97.4× | — |
| Poly Medicure Limited | 15%/yr | 51.2× | ₹3.4 |
| Fischer Medical Ventures Limited | 831%/yr | 84.9× | — |
| Tarsons Products Limited | — | 150.2× | — |
| QMS Medical Allied Services Limited | — | 34.0× | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Medical Equipment & Supplies), it ranks 2 of 8 on returns, 3 of 6 on growth, 4 of 8 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 15% on capital, ahead of 75% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹59 crore of cash from the business and spent ₹53 crore on plant and equipment, with ₹6 crore to spare; it still raised ₹85 crore from shareholders — borrowings did not rise. And the profit is real: of every 100 rupees it reported over 7 years, about 153 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back more slowly than it used to: it went from being paid 3 days before it paid its own suppliers to waiting 182 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
6 of 9 checks clear · 67%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Announced 11 Aug 2026 · Consolidated · Unaudited
Revenue
₹75 Cr
Revenue vs last year
+13.2%
Revenue vs last quarter
+0.9%
Net profit
₹10 Cr
Profit vs last year
+28.9%
Profit vs last quarter
+3.1%
Net margin
13.8%
EPS
₹1.87
Earnings call transcript · 12 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹1,078 Cr
- Prev close
- ₹195.92
- 52w High
- ₹345
- 52w Low
- ₹156
- Enterprise value
- ₹1,068 Cr
- Beta
- 1.3
- Price CAGR 1y
- -40.0%
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 9.8%
- PEG ratio
- 0.3
- P/E ratio
- 31.0
- P/B ratio
- 4.4
- EV / EBITDA
- 23.2
- Industry P/E
- 58.3
- ROCE
- 15.0%
- ROCE 5y average
- 10.4%
- ROE
- 14.8%
- Debt / Equity
- 0.1
- Interest coverage
- 15.5
- Dividend yield
- 0.0%
- ROE 3y average
- 22.0%
- ROE last year
- 15.0%
Annual P&L
- Annual revenue
- ₹278 Cr
- Annual profit
- ₹29 Cr
- Operating margin
- 16.0%
- Net profit margin
- 10.4%
- EBITDA margin
- 15.8%
- Sales growth 3y
- 19.7%
- Sales growth 5y
- 24.8%
- Profit growth 3y
- 124.0%
- Profit growth 5y
- 103.0%
- EPS
- ₹5.3
- Sales growth TTM
- 17.0%
- Profit growth TTM
- 50.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹75 Cr
- Profit latest quarter
- ₹10 Cr
- YoY quarterly sales growth
- 13.9%
- YoY quarterly profit growth
- 25.0%
- OPM latest quarter
- 19.2%
Balance Sheet
- Book Value
- ₹44.2
- Face Value
- ₹2.0
- Total debt
- ₹13 Cr
- Total cash
- ₹10 Cr
- Borrowings
- ₹13 Cr
- Reserves / Equity
- 21.1
Cash Flow
- Operating cash flow
- -₹5 Cr
- Free cash flow
- -₹23 Cr
- FCF yield
- -2.3%
- Net cash flow
- -₹101 Cr
Shareholding
- Promoter holding
- 41.8%
- FII holding
- 30.1%
- DII holding
- 10.9%
- Public holding
- 17.2%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnosti | 1,495.25 | 79.3 | 17,231 | 0.00 | 56.6 | 522.3 | 399.4 | 319.0 | 18.0 |
| Poly Medicure | 1,599.00 | 50.6 | 16,208 | 0.22 | 85.3 | -7.6 | 525.4 | 30.3 | 12.5 |
| Fischer Medical | 32.11 | 91.6 | 2,243 | 0.15 | 3.8 | -22.0 | 81.9 | 249.5 | 11.4 |
| Tarsons Products | 336.30 | 151.1 | 1,789 | 0.00 | -1.4 | -180.9 | 110.2 | 20.7 | 4.6 |
| Q-Line Biotech | 675.00 | 27.8 | 1,575 | 0.00 | 34.4 | 147.3 | 197.9 | -8.6 | 22.4 |
| Laxmi Dental | 194.20 | 30.7 | 1,069 | 0.00 | 10.3 | 22.8 | 74.7 | 13.9 | 15.1 |
| Hemant Surgical | 634.00 | 54.4 | 922 | 0.00 | 12.8 | 159.2 | 166.7 | 189.2 | 18.9 |
| Median | 330.00 | 36.3 | 666 | 0.00 | 4.2 | 19.8 | 74.7 | 21.5 | 15.1 |
Competes with: Fischer Medical Ventures Limited, GKB Ophthalmics Limited, Molbio Diagnostics Limited, Nureca Limited, Poly Medicure Limited, QMS Medical Allied Services Limited, Tarsons Products Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 55 | 60 | 57 | 62 | 61 | 66 | 72 | 66 | 74 | 75 |
| Expenses | 44 | 43 | 46 | 48 | 52 | 51 | 54 | 61 | 59 | 60 | 60 |
| Material Cost | 4.11 | 2.35 | 6.94 | 4 | 12 | 9.11 | |||||
| Change in Inventories | -0.47 | 1.56 | 0.21 | 0.67 | -2.91 | -2.74 | |||||
| Purchases of Stock-in-Trade | 9.25 | 14 | 16 | 15 | 13 | 9.63 | |||||
| Employee Cost | 24 | 24 | 26 | 26 | 27 | 28 | |||||
| Other Expenses | 14 | 13 | 13 | 13 | 12 | 16 | |||||
| Operating Profit | 4 | 12 | 14 | 9 | 10 | 10 | 12 | 11 | 7 | 14 | 14 |
| OPM % | 8.22 | 21 | 23 | 15 | 16 | 16 | 18 | 15 | 11 | 18 | 19 |
| Other Income | -0 | -0 | 6 | 1 | 1 | 2 | 2 | 2 | -4 | 2 | 2 |
| Exceptional items (within Other Income) | 0.41 | 0 | 0 | -5.78 | 0 | 0 | |||||
| Interest | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | -1 | 7 | 16 | 5 | 5 | 6 | 10 | 9 | -1 | 11 | 12 |
| Tax % | -140 | 16 | 11 | 23 | 23 | 41 | 24 | 20 | -175 | 4 | 21 |
| Net Profit | 2 | 8 | 17 | 6 | 5 | 4 | 8 | 9 | 2 | 10 | 10 |
| EPS in Rs | 74 | 244 | 6.04 | 2.12 | 0.93 | 0.78 | 1.53 | 1.55 | 0.36 | 1.83 | 1.87 |
| Diluted EPS in Rs | 0.78 | 1.52 | 1.58 | 0.36 | 1.83 | 1.87 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 150 | 92 | 137 | 162 | 194 | 239 | 278 | 287 |
| Expenses | 146 | 88 | 130 | 152 | 169 | 196 | 234 | 241 |
| Material Cost | 37 | 25 | ||||||
| Change in Inventories | 0.56 | -0.47 | ||||||
| Purchases of Stock-in-Trade | 19 | 58 | ||||||
| Employee Cost | 86 | 102 | ||||||
| Other Expenses | 54 | 50 | ||||||
| Operating Profit | 3 | 4 | 7 | 9 | 24 | 43 | 44 | 46 |
| OPM % | 2.30 | 4.60 | 4.80 | 6 | 13 | 18 | 16 | 16 |
| Other Income | 2 | 0 | -10 | 2 | 0 | 10 | 3 | 3 |
| Exceptional items (within Other Income) | 7.03 | -5.78 | ||||||
| Interest | 3 | 3 | 4 | 4 | 6 | 6 | 2 | 1 |
| Depreciation | 7 | 6 | 8 | 11 | 12 | 15 | 16 | 17 |
| Profit before tax | -4 | -4 | -16 | -5 | 6.92 | 31 | 29 | 31 |
| Tax % | 5 | 8 | 15 | 4 | -136 | 21 | 9 | |
| Net Profit | -5 | -5 | -19 | -4 | 25 | 32 | 29 | 31 |
| EPS in Rs | -155 | -156 | -597 | -129 | 805 | 5.78 | 5.27 | 5.61 |
| Diluted EPS in Rs | 6.05 | 5.53 | ||||||
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 25%
- 3 years
- 20%
- TTM
- 17%
Compounded profit growth
- 10 years
- —
- 5 years
- 103%
- 3 years
- 124%
- TTM
- 50%
Stock price CAGR
- 10 years
- —
- 5 years
- —
- 3 years
- —
- 1 year
- -40%
Return on equity
- 10 years
- —
- 5 years
- 18%
- 3 years
- 22%
- Last year
- 15%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 11 | 11 |
| Reserves | 37 | 33 | 9 | 6 | 31 | 198 | 232 |
| Borrowings | 37 | 39 | 50 | 50 | 61 | 20 | 13 |
| Other Liabilities | 31 | 34 | 43 | 40 | 46 | 60 | 40 |
| Minority Interest | 0.16 | 0.79 | |||||
| Total Liabilities | 106 | 106 | 103 | 97 | 139 | 288 | 297 |
| Fixed Assets | 39 | 42 | 40 | 40 | 46 | 51 | 63 |
| CWIP | 0 | 7 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 6 | 10 | 27 |
| Other Assets | 66 | 56 | 63 | 56 | 87 | 227 | 207 |
| Total Assets | 106 | 106 | 103 | 97 | 139 | 288 | 297 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 12 | 10 | -2 | 14 | 8 | 44 | -5 |
| Cash from Investing Activity | -18 | -9 | 3 | -10 | -11 | -29 | -78 |
| Cash from Financing Activity | 6 | -0 | -4 | -1 | -3 | 111 | -18 |
| Net Cash Flow | 0 | 0 | -3 | 3 | -5 | 125 | -101 |
| Free Cash Flow | -5 | 0 | -0 | 5 | -5 | 29 | -23 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 64 | 54 | 46 | 47 | 56 | 60 |
| Inventory Days | 186 | 305 | 272 | 212 | 397 | 156 | |
| Days Payable | 197 | 273 | 245 | 197 | 585 | 68 | |
| Cash Conversion Cycle | 54 | 96 | 81 | 61 | 47 | -132 | 147 |
| Working Capital Days | 13 | 3 | -3 | -13 | 0 | 37 | 182 |
| ROCE % | 3 | -1 | 1 | 18 | 19 | 15 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
-9.70inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
1.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
News
News and filings about Laxmi Dental Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Biocompatible 3D-printing resins — aligner/model printing (Taglus)
- CAD/CAM milling machines & scanners (capital equipment)
- Cobalt-chromium alloy — for PFM/metal crowns & frameworks
- Dental porcelain / ceramic powders — for PFM & ceramic crowns
- PETG thermoforming sheets — clear aligners (Taglus)
- PMMA discs — for dentures & temporaries
- TPU thermoforming sheets — clear aligners (Taglus)
- Zirconia blocks/discs (YSZ) — for Illusion Zirconia branded crowns
Sells to
- Domestic dental laboratories (Taglus aligner materials & machines) · thermoforming aligner sheets, 3D-printing resins, aligner machines
- Heartland Dental (US DSO / Diamond Trusted Network partner) · custom dental prosthetics via US lab (export laboratory)
- Indian dental clinics & dentists (22,000+ clinics, 320 cities) · custom dental prosthetics — crowns, bridges, zirconia/PFM, dentures, clear aligners
- International dental labs & clinics (USA/UK/Europe, 90+ countries; exports ~33-34% of revenue) · custom dental prosthetics & aligners (export)
- Own US subsidiaries — Diverse Dental Lab (NJ) & Solitaire Smile Dental Lab / Laxmi Dental Lab USA (Teterboro NJ) · dental prosthetics for US distribution (intercompany)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Medical Equipment & Supplies
- Classification
- Healthcare › Medical Equipment & Supplies
- ISIN
- INE0WO601020
Business segments
- Laboratory Business · 70%
- Aligners Business · 27%
- Other business · 3%
Plants
- Ahmedabad support facility
- Bengaluru support facility
- Boisar cluster (2 facilities) — Taglus / aligners
- Delhi support facility
- Diverse Dental Lab (US subsidiary)
- Illusion Dental Lab — Mira Road cluster (3 facilities)
- Kochi facility — Kids-e-Dental
- Mumbai support facilities (2) + registered office
- Solitaire Smile Dental Lab / Laxmi Dental Lab USA (US subsidiary)
News impact
Big market events that reach Laxmi Dental Limited, and how the effect spreads.
28 Jun, 14:22 IST · Market event · medium impact
Health ministry proposes amendments to Medical Devices Rules
Who it hits first
- Domestic medical-device manufacturers face simpler and faster licensing under the proposed Medical Devices Rules amendments; lower compliance cost and quicker product approvals primarily benefit pure-play domestic makers (POLYMED, LAXMIDENTL).
Who may gain
- Poly Medicure (POLYMED) — largest listed pure-play domestic device maker
- Laxmi Dental (LAXMIDENTL) — domestic dental-device maker
Along the supply chain
Downstream
Hospitals, diagnostic chains and distributors that buy domestic devices may get faster product availability and modestly better pricing as licensing friction falls.
Upstream
Upstream component/raw-material suppliers (medical-grade polymers, electronics) see no direct change — the benefit is regulatory (licensing friction), not input-sourcing driven.
Where demand moves
Business
Eased licensing lowers entry/expansion friction for domestic device makers (POLYMED, LAXMIDENTL), supporting import substitution in an ~82%-import-dependent market; import-led players (NURECA) face an ambiguous net effect since registration may also speed up.
Capital
Marginal positive sentiment toward listed domestic device makers; the draft (non-final) status is too soft to drive sector rotation, so capital impact is limited to stock-specific re-rating if the final rule confirms the easing.
How it spreads across sectors
Healthcare
Marginal positive for device-using hospitals and diagnostic chains via faster device availability
Medical Devices
Lower regulatory friction → margin/throughput tailwind for domestic device makers
When it plays out
Immediate
Muted price reaction expected — this is a draft notification, not a final rule (historical precedent: POLYMED 1d +0.85% / -0.90% on 2023 policy events).
Medium term
If finalized, lower compliance cost and faster approvals reinforce the domestic-manufacturing tailwind (POLYMED renal +35% YoY in FY24 after Oct-23 device rules); 1-6 month positive for POLYMED and LAXMIDENTL.
Short term
Watch for consultation feedback and the final notification; domestic device-maker sentiment modestly positive.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Splits, bonuses & buybacks
- daily-prices repair: 3 rows from NSE's archive (replace 1, delete 1, insert 1), 2025-03-18..2026-02-01 (docs/flat_day_repair.md)1× · 18 Mar 2025
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 22 May 2026 | NEO APEX SHARE BROKING SERVICES LLP | BUY | 3,42,346 | ₹247.65 |
| 22 May 2026 | NEO APEX SHARE BROKING SERVICES LLP | SELL | 3,42,346 | ₹249.28 |
| 22 May 2026 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | BUY | 2,78,074 | ₹248.94 |
| 22 May 2026 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | SELL | 2,78,074 | ₹249.28 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-263 Sep 2026
- Earnings call13 Aug 2026
- Earnings call · Q1FY2712 Aug 2026
- Earnings call · Q3FY2611 Feb 2026
- Annual report · 2024-256 Sep 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.